Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study:

A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases

Rationale:

Radiation therapy uses high energy x-rays to kill tumor cells.

Purpose:

This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain metastases.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Cognitive/Functional Effects
Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: cognitive assessment
Procedure: quality-of-life assessment
Radiation: intensity-modulated radiation therapy
Radiation: whole-brain radiation therapy
Phase 2

Verified by Radiation Therapy Oncology Group January, 2014

Sponsored by: Radiation Therapy Oncology Group
Information provided by: Radiation Therapy Oncology Group
ClinicalTrials.gov identifier: NCT01227954

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Minesh P. Mehta, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site